Compare NPKI & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | MLTX |
|---|---|---|
| Founded | 1932 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | N/A | 2020 |
| Metric | NPKI | MLTX |
|---|---|---|
| Price | $13.53 | $16.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $14.17 | ★ $30.58 |
| AVG Volume (30 Days) | 722.6K | ★ 933.3K |
| Earning Date | 04-30-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.60 | N/A |
| Revenue Next Year | $12.80 | N/A |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $5.95 |
| 52 Week High | $15.85 | $62.75 |
| Indicator | NPKI | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.55 | 40.75 |
| Support Level | $13.31 | $14.84 |
| Resistance Level | $14.00 | $16.69 |
| Average True Range (ATR) | 0.51 | 0.72 |
| MACD | -0.03 | -0.28 |
| Stochastic Oscillator | 33.97 | 1.10 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.